Shilpa Medicare rises 3% on USFDA approval for Imatinib Mesylate tabletshttps://www.moneycontrol.com/news/business/stocks/shilpa-medicare-rises-3-on-usfda-approval-for-imatinib-mesylate-tablets-3406511.html#SHILPAMED